HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-27-2004, 08:21 PM   #1
Merridith
Guest
 
Posts: n/a
Molecular test predicts risk of breast cancer recurrence
Source: (cancerfacts.com)
Friday, December 10, 2004

SAN ANTONIO – Dec. 10, 2004 – Researchers have moved a giant step closer to being able to determine which breast cancer patients are most likely to experience recurrence and which are least likely to, according to a new test presented today at the San Antonio Breast Cancer Symposium.

The gene test performed on a tissue sample taken from the tumor, can predict both the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy, thus potentially giving physicians the most precise treatment planning information yet.

Dr. Norman Wolmark, chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP), which performed the research in collaboration with the National Cancer Institute and Genomic Health, Inc, which developed the assay, says the test could change standard practice for treating breast cancer.

"These data advance the state of the art in cancer care and call for a re-evaluation of treatment practice. By using the Oncotype DX assay, physicians can more effectively optimize a treatment plan and avoid under treating and over treating breast cancer patients," said Wolmark in a news release.

The advance is considered so significant, the New England Journal of Medicine published the results of the study online today ahead of the print edition next week.

Using samples from 447 patients and a collection of 250 genes in three independent preliminary studies, the researchers identified a panel of 16 cancer-related genes, the status of which best predicted recurrence.

Using a "recurrence score" based on the expression patterns of these genes in the tumor sample, they were able to more accurately predict the risk of recurrence than is now possible with current tests. Gene expression patterns refer to gene activity, or protein production. Active genes are producing proteins, and non-active genes are not.

The researchers then used tissue samples and medical records from 668 women enrolled in clinical trials of the cancer drug tamoxifen.

Using biopsy tissue and medical records they divided the women into low, intermediate, and high risk of recurrence groups based on the recurrence score. They found that 51 percent were in the low risk group, 22 percent were at intermediate risk, and 27 percent were at high risk group.

These risk group divisions correlated well with the actual rates of recurrence of breast cancer after 10 years as shown on the women's medical records. There was a significant difference in recurrence rates between women in the low and high risk groups. They found there was a 6.8 percent rate of recurrence at 10 years in the low-risk group, a 14.3 percent risk in the intermediate-risk group and a 30.5 percent chance of recurrence within 10 years of initial treatment in the high risk group.

The researchers also presented new results indicating that the same test can predict which women benefit most from chemotherapy. They were able to estimate that about half of the 50,000 U.S. women may be at low risk for recurrence and may not need to undergo chemotherapy with all its adverse side effects.

The significant advance of this study is that the genomic analysis is conducted using thin sections from standard diagnostic pathology specimens that are routinely available, making the test widely accessible. Previously, such genomic testing, as it is called, required frozen tissue samples, which are much more difficult and cumbersome to obtain for routine testing.

"The test has the potential to change medical practice by sparing thousands of women each year from the harmful short- and long-term side effects associated with chemotherapy," said Dr. JoAnne Zujewski, M.D., senior investigator in NCI's Cancer Therapy Evaluation Program.

http://www.cancerfacts.com/Home_News.asp?C...d=4&NewsId=1774
  Reply With Quote
Old 02-18-2005, 10:40 AM   #2
AlaskaAngel
Guest
 
Posts: n/a
For node-negative bc:

Gene expression profile predicts breast cancer metastases

Reuters Health
Posting Date: February 17, 2005

Last Updated: 2005-02-17 18:30:23 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Researchers have identified a gene expression signature that is a powerful predictor of distant metastases in patients with lymph node-negative breast cancer.

"Since only 30% to 40% of untreated lymph node-negative patients develop tumor recurrence, our prognostic signature could provide a powerful tool to identify those patients at low risk, preventing overtreatment in substantial numbers of patients," senior author Dr. John Foekens, from Erasmus Medical Center in Rotterdam, the Netherlands, and colleagues note.

As reported in the February 19th issue of The Lancet, the researchers analyzed 22,000 RNA transcripts from breast cancer samples to identify an expression profile that predicted metastases. The samples came from 286 patients with node-negative disease.

Using a training set of 115 tumor specimens, the authors identified a 76-gene signature that predicted distant metastases. Subsequent testing of this signature in a set of 171 lymph node-negative patients yielded a sensitivity and specificity of 93% and 48%, respectively.

The profile was found to be useful in predicting metastatic disease even after adjusting for traditional prognostic factors. Moreover, the signature was particularly good at predicting metastases within 5 years; patients with the signature were nearly six times more likely to develop metastases than patients lacking this profile.

The investigators found that the signature was a strong predictor of metastases regardless of menopausal status and also performed well in patients with tumors between 10 to 20 mm, a group that has traditionally proved to be a prognostic challenge.

In a related editorial, Dr. Tor-Kristian Jenssen, from PubGene AS in Vinderen, Norway, and Dr. Eivind Hovig, from the Norwegian Radium Hospital in Montebello, note that although the current study represents the largest of its kind to date, "it may still be too small to provide a final selection of genes for signature inclusion. Thus, the signature is there, but it is still necessary to read the fine print."

Lancet 2005;365:634-635,671-679.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:50 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter